A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with advanced solid tumors will receive
investigational study drug ARRY-438162 (MEK162).
This study has 3 parts. In the first part, patients with advanced solid tumors will receive
increasing doses of study drug in order to achieve the highest dose of the study drug
possible that will not cause unacceptable side effects. Approximately 30 patients from the US
will be enrolled in Part 1. (Active, not recruiting)
In the second part of the study, patients with advanced or metastatic biliary cancer will
receive the best dose of study drug determined from the first part of the study and will be
followed to see what side effects and effectiveness the study drug has, if any, in treating
the cancer. Approximately 25 patients from the US will be enrolled in Part 2. (Active, not
recruiting)
In the third part of the study, patients with metastatic colorectal cancer (CRC) will receive
the best dose of the study drug determined from the first part of the study and will be
followed to see what side effects and effectiveness the study drug has, if any, in treating
the cancer. Approximately 25 patients with KRAS mutation (Active, not recruiting) and 15
patients with BRAF mutation (Active, not recruiting) from the US will be enrolled in Part 3.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer